H.C. Wainwright lowered the firm’s price target on Kala Pharmaceuticals to $21 from $22 and keeps a Buy rating on the shares following the Q4 report. The firm says positive data from the CHASE trial could allow the company to advance KPI-012 into a second pivotal trial to support a biologics license application submission.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
